Saol lands up to $115M from Oaktree for rare-disease drug launch
What's the deal? Saol Therapeutics has secured up to $115 million in milestone-based debt financing from funds managed by OaktreeDealroom has a profile for this one. Try Dealroom →. An initial tranche funds near-term launch readiness for SL1009, the clinical-stage company's rare-disease candidate, with the rest released as regulatory, clinical, and commercial milestones are met. The transaction closed on September 11, 2026.
What's the endgame? Saol is preparing to commercialise SL1009 (sodium dichloroacetate), an investigational treatment for pyruvate dehydrogenase complex deficiency, a rare, life-threatening mitochondrial disease with no FDA-approved therapies. Additional capital would fund pipeline expansion, including SL1009 for Congenital Lactic Acidosis and SL1002 for further pain indications and spasticity.
Why now? Saol filed an NDA resubmission for SL1009 on June 30, 2026, and the FDA has set a target action date of December 30, 2026. The drug carries Priority Review, Orphan Drug, and Rare Pediatric Disease designations, and Saol expects a Priority Review Voucher on approval. The company also received a Notice of Allowance from the US Patent and Trademark Office covering a method of administering SL1009 to patients on a ketogenic diet, with the patent set to expire in 2045.
What did they say? "This financing gives Saol the capital to prepare a commercial organization for the launch of SL1009 while funding the next phase of our pipeline," said Dave Penake, chief executive officer of Saol Therapeutics.
What could go wrong? SL1009 is not yet approved for any indication, and the milestone structure means much of the capital hinges on hitting regulatory and commercial targets. A negative or delayed FDA decision would leave the later tranches unlocked.
The signal: The deal ranks in the 96th percentile by size among US health-sector debt rounds tracked all-time — a sign that lenders are willing to write large milestone-based cheques for rare-disease drugs nearing approval. As Oaktree's Kent Bailey put it, the facility "reflects Oaktree's confidence in Saol's experienced management team."
Read more: pr.holladayjournal.com
Image credit: foteih
